Squamous cell carcinoma is one of the most common and aggressive types of cancer in the head and neck region. It is the fifth ...

ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg Updated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC ...

Breast carcinoma develops from breast duct or lobule cells and is influenced by age, genetics, hormones, obesity, and alcohol ...

Bladder carcinoma usually arises from the urothelium and is strongly linked to smoking and chemical exposure. It often ...

Scientists at The University of Texas at El Paso have found a promising new target in the fight against high-grade serous carcinoma, an aggressive form of ovarian cancer.

Actor Dave Coulier, best known for his role in the sitcom “Full House,” recently sat down with CURE to discuss facing cancer ...

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST ...

Werewolf Therapeutics (HOWL) announced a pipeline update, including a review of recent data for its INDUKINE programs, and a business overview of ...